New T2D study for patients currently taking only oral meds or no meds for diabetes
Please fill in your details
About the Study
This study is for those with Type 2 Diabetes using only oral meds or no meds for their diabetes. Participants will add either a once weekly injection of CagriSema or placebo to their current treatment. CagriSema is an investigational combination medication of Cagrilinitide and Semaglutide.
The goal of the study is to see how well the investigational med, CagriSema, helps with weight loss.
Participants will receive the study med at no charge, and will be compensated for their time and travel.
Participant Eligibility Criteria ( To take part in the study )
- Diagnosed with Type 2 Diabetes
- A1C between 7.0% and 10.0%
- Overweight or Obese
- Taking only oral meds or no meds for diabetes